Hyuna Park1,2, Minkyu Jung3, Min Jae Kim1,2, Jihee Min1,2, Choong-Kun Lee3, Sang Joon Shin3, Seung-Hoon Beom3, Joong Bae Ahn4, Justin Y Jeon5,6,7. 1. Exercise Medicine Center for Diabetes and Cancer Patients, ICONS, Yonsei University, Shinchon-dong, Seodaemun-gu, Seoul, 120-749, Republic of Korea. 2. Department of Sport Industry Studies, Yonsei University, Shinchon-dong, Seodaemun-gu, Seoul, 120-749, Republic of Korea. 3. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea. 4. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, 03722, South Korea. vvswm513@yuhs.ac. 5. Exercise Medicine Center for Diabetes and Cancer Patients, ICONS, Yonsei University, Shinchon-dong, Seodaemun-gu, Seoul, 120-749, Republic of Korea. jjeon@yonsei.ac.kr. 6. Department of Sport Industry Studies, Yonsei University, Shinchon-dong, Seodaemun-gu, Seoul, 120-749, Republic of Korea. jjeon@yonsei.ac.kr. 7. Cancer Prevention Center, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea. jjeon@yonsei.ac.kr.
Abstract
PURPOSE: Although adjuvant chemotherapy can have an impact on physical activity (PA), PA level has not been studied in patients with stage II-III colon cancer. This study investigated PA levels during and between chemotherapy cycles. METHODS: We objectively measured PA levels for 2 weeks during the 2nd and 11th chemotherapy cycles. In addition, self-reported PA levels were assessed before chemotherapy initiation, during 2nd, 6th, and 12th chemotherapy cycles. This study included 22 men and 33 women with stage II-III colon cancer patients (57 ± 9 years). RESULTS: Before the initiation of chemotherapy, most cancer patients were minimally active. Compared with the 1st week of chemotherapy, moderate- and light-intensity PA levels significantly increased during the 2nd week of chemotherapy. Patients increased moderate- and light-intensity PA from 217.4 to 290.3 min per week and from 585.7 to 657.8 min per week, respectively (p < 0.01). PA levels did not show any difference between the 2nd and 12th cycles when objectively measured, or between baseline and 2nd, 6th, and 12th cycles when self-reported. CONCLUSION: PA levels during chemotherapy cycles are initially low, and then increase towards the end of the cycle; however, PA levels do not change between chemotherapy cycles. Future work with broader and larger samples size is recommended.
PURPOSE: Although adjuvant chemotherapy can have an impact on physical activity (PA), PA level has not been studied in patients with stage II-III colon cancer. This study investigated PA levels during and between chemotherapy cycles. METHODS: We objectively measured PA levels for 2 weeks during the 2nd and 11th chemotherapy cycles. In addition, self-reported PA levels were assessed before chemotherapy initiation, during 2nd, 6th, and 12th chemotherapy cycles. This study included 22 men and 33 women with stage II-III colon cancerpatients (57 ± 9 years). RESULTS: Before the initiation of chemotherapy, most cancerpatients were minimally active. Compared with the 1st week of chemotherapy, moderate- and light-intensity PA levels significantly increased during the 2nd week of chemotherapy. Patients increased moderate- and light-intensity PA from 217.4 to 290.3 min per week and from 585.7 to 657.8 min per week, respectively (p < 0.01). PA levels did not show any difference between the 2nd and 12th cycles when objectively measured, or between baseline and 2nd, 6th, and 12th cycles when self-reported. CONCLUSION: PA levels during chemotherapy cycles are initially low, and then increase towards the end of the cycle; however, PA levels do not change between chemotherapy cycles. Future work with broader and larger samples size is recommended.
Authors: Ian R Kleckner; Richard F Dunne; Matthew Asare; Calvin Cole; Fergal Fleming; Chunkit Fung; Po-Ju Lin; Karen M Mustian Journal: Oncol Hematol Rev Date: 2018-02-15